The Role of Microbiome in Cancer Therapy
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Best tumor response, defined as a complete response or a clear decrease in tumor burden
研究概览
简要总结
This research trial studies the gut microbiome in fecal samples from patients with cancer that has spread to other parts of the body who are undergoing chemotherapy or immunotherapy. Studying samples of feces from patients with metastatic cancer in the laboratory may help doctors learn if the make-up of the gut microbiome has a positive or negative influence to a patient's response to chemotherapy or immunotherapy.
详细描述
PRIMARY OBJECTIVES:
I. To quantitatively determine the composition of the microflora and their gene and protein expression levels in patients with metastatic colorectal cancer being treated with fluorouracil (5-FU) based chemotherapy, or anti-PD1 immunotherapy.
SECONDARY OBJECTIVES:
I. Compare the changes in species composition and in the metabolic activities (as determined in the primary objective) with response to chemotherapy or immunotherapy.
II. Compare the changes in species composition and in the metabolic activities (as determined in the primary objective) with toxicities and side effects resulting with chemotherapy or immunotherapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be willing and able to provide fecal samples according to protocol schedule
- •Diagnosis of metastatic colorectal cancer, where the metastatic disease has not been previously treated
- •Scheduled to begin fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or folinic acid-fluorouracil-irinotecan (FOLFIRI) based chemotherapy for the advanced disease
- •Must have radiologic evidence of disease
- •Diagnosis of metastatic cancer
- •Scheduled to begin pembrolizumab or another anti-PD-1 or anti-PD-L1 antibody as single agent therapy for the treatment of the advanced disease
- •Must have physical or radiologic evidence of disease
排除标准
- •Patients with a colostomy or any other issues that may prevent the standard methods for collection of stool are not eligible for this study
- •Patients are not enrolled or a research protocol for treatment
结局指标
主要结局
Best tumor response, defined as a complete response or a clear decrease in tumor burden
时间窗: Up to 2 years
The presence and amounts of species and their protocols will be compared to tumor response.
次要结局
未报告次要终点